Help paying · Medicare negotiated price · pharmacy cost · cycle 2027
Vraylar (cariprazine): where help paying exists, what Medicare negotiated and what pharmacies pay
Medicare's negotiated price for a 30-day supply is $770 on January 1, 2027. 1 non-manufacturing label change is dated in the last 12 months in the FDA's file. ClinicalTrials.gov lists 6 recruiting trials that name cariprazine.
Every package we can price
Per-unit prices (per each unit, as the files state). "Scheduled" is a price the CMS file already dates for the future.
| NDC | Product | Unit | Negotiated now | Scheduled | NADAC | Share |
|---|---|---|---|---|---|---|
| 61874-0115-11 | VRAYLAR CAPSULES 1.5MG (Inner Pack) | EA | n/a | $26.99 | $50.83 | - |
| 61874-0115-17 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 61874-0115-20 | VRAYLAR CAPSULES 1.5MG | EA | n/a | $26.99 | $50.83 | - |
| 61874-0115-30 | VRAYLAR (Cariprazine) 1.5MG | EA | n/a | $26.99 | $50.83 | - |
| 61874-0115-31 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 61874-0115-63 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 61874-0115-90 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 61874-0130-11 | VRAYLAR CAPSULES 3MG (Inner Pack) | EA | n/a | $26.99 | $50.86 | - |
| 61874-0130-20 | VRAYLAR CAPSULES 3MG | EA | n/a | $26.99 | $50.86 | - |
| 61874-0130-30 | VRAYLAR (Cariprazine) 3MG | EA | n/a | $26.99 | $50.86 | - |
| 61874-0130-31 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 61874-0130-63 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 61874-0130-90 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 61874-0145-11 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 61874-0145-30 | VRAYLAR (Cariprazine) 4.5MG | EA | n/a | $26.99 | $50.78 | - |
| 61874-0145-63 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 61874-0145-90 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 61874-0160-11 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 61874-0160-30 | VRAYLAR (Cariprazine) 6MG | EA | n/a | $26.99 | $50.76 | - |
| 61874-0160-63 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 61874-0160-90 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 61874-0170-08 | VRAYLAR (Cariprazine) 1.5MG / 3MG Blister | n/a | n/a | $110 | n/a | no NADAC price |
| 61874-0250-30 | Vraylar Capsules 0.5 MG 30 | EA | n/a | $26.99 | $50.77 | - |
| 61874-0275-30 | Vraylar Capsule 0.75 MG 30 | EA | n/a | $26.99 | $50.81 | - |
| 70518-3157-00 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
| 70518-3157-01 | (name not listed) | n/a | n/a | $26.99 | n/a | no NADAC price |
When could a generic arrive
Each date below is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
| Application | Product | Latest listed patent expiry | Latest listed exclusivity expiry | Latest of the two | Set by |
|---|---|---|---|---|---|
| NDA204370 | Vraylar (cariprazine) 1.5mg, Vraylar (cariprazine) 3mg, Vraylar (cariprazine) 4.5mg, Vraylar (cariprazine) 6mg and 4 more | March 17, 2030 | June 18, 2029 | March 17, 2030 | patent 7737142 with its pediatric extension; 67 dated entries listed |
Source: FDA Orange Book data files, edition September 2026, read November 7, 2026; patent listings are as submitted by applicants and not verified by FDA. FDA data file.
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Vraylar of $1.14 billion in 2024, across 766,962 claims and 117,573 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $1.14 billion | 766,962 | 117,573 | $1,481 |
| 2023 | $935.65 million | 633,278 | 98,229 | $1,477 |
| 2022 | $708.77 million | 509,082 | 73,893 | $1,392 |
| 2021 | $583.11 million | 436,709 | 63,398 | $1,335 |
| 2020 | $487.50 million | 375,543 | 56,285 | $1,298 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 1 states with the largest reimbursement are shown. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| KY | 100 | $76,975 | All record types |
A state missing from the table means its figures were suppressed or not reported, not zero use. 238 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
No program in our finder currently lists this drug as open to new patients.
Label changes
FDA actions on the applications behind Vraylar dated since November 11, 2025, leaving out manufacturing (CMC) changes. 1 change in the window.
| Date | Class | Application | Submissions | FDA documents |
|---|---|---|---|---|
| December 18, 2025 | Efficacy | NDA204370 | 14, 15, 16, 17 | Label (PDF) posted December 22, 2025FDA letter posted December 19, 2025 |
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Clinical trials recruiting
ClinicalTrials.gov lists 6 interventional trials that name cariprazine and are recruiting, and 5 more not yet recruiting. By phase: Phase 4: 2, Phase 3: 2, Phase 1: 1, PHASE1/PHASE2: 1. The 6 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT05913947 | Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)Depression, Bipolar | Phase 4 | Aalborg University Hospital | October 29, 2026 | Denmark |
| NCT07484204 | Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With SchizophreniaSchizophrenia | Phase 1 | Anxo Pharmaceutical Co., Ltd. | September 16, 2026 | India |
| NCT04777357 | A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.Depression; Bipolar I Disorder | Phase 3 | AbbVie | July 27, 2026 | United States, Puerto Rico, Russia |
| NCT07266545 | RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)Unipolar Depression; Bipolar Depression | Phase 4 | Mayo Clinic | June 22, 2026 | United States |
| NCT07185815 | Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral CariprazineSchizophrenia; Bipolar I Disorder; Major Depressive Disorder | Phase 1 / Phase 2 | Mapi Pharma Ltd. | May 1, 2026 | India, Israel |
| NCT03817502 | Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With SchizophreniaSchizophrenia | Phase 3 | Gedeon Richter Plc. | October 8, 2025 | United States, Bulgaria, Colombia and 5 more |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Vraylar?
The CMS file publishes $770 from January 1, 2027. This is a price CMS agreed with the manufacturer for Medicare Part D, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
The two CMS files do not give a comparable per-unit price for this drug.
Is there help paying for Vraylar?
No program in our finder lists this drug yet.
When could a generic version of Vraylar arrive?
For Vraylar, the FDA's Orange Book (edition September 2026) lists these latest patent or exclusivity expiry dates by application: NDA204370, March 17, 2030. Each date is an upper bound from listed patent and exclusivity dates, not a forecast of when a generic will launch. Basis: latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled).
Can I join a clinical trial for Vraylar?
ClinicalTrials.gov lists 6 recruiting interventional trials that name cariprazine (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Vraylar?
CMS's Medicare Part D spending dataset reports gross spending on Vraylar of $1.14 billion in 2024, across 766,962 claims and 117,573 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/vraylar.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; FDA Drugs@FDA and Orange Book data files; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.